Author: Burak Erdem (Turkey)
Co-authors: Mustafa Gok
Purpose
To investigate the effects of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) on systemic inflammatory and cardiovascular biomarkers in treatment-naive patients with neovascular age-related macular degeneration (nAMD)
Setting/Venue
Ordu University Training and Research Hospital
Methods
This study included 24 eyes of 24 patients treated with 0.5 mg ranibizumab (IVR group) and 25 eyes of 25 patients treated with 2.0 mg aflibercept (IVA group). Complete blood count, C-reactive protein (CRP), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), uric acid (UA), albumin, fibrinogen levels were measured in blood samples before and after the three-monthly loading dose treatment. Neutrophil/lymphocyte ratio (NLR), monocyte/HDL-c ratio (MHR), CRP/albumin ratio (CAR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR) were also calculated.
Results
A statistically significant decline was determined in post-treatment CRP (P=0.002), LDL-c (P=0.001) levels, white blood cell (WBC, P=0.001), neutrophil (P=0.001), monocyte (P=0.019) counts and NLR (P=0.020), MHR (P=0.042), CAR (P=0.010) ratios comparing with pre-treatment values in the IVA group. No statistically significant change was found in any of the parameters evaluated in the study in the IVR group. Also, there was no significant change in fibrinogen, lymphocyte count, MLR, HDL-c, UA, PLR, and platelet count values in both groups.
Conlusions
Compared to IVR, IVA treatment had a small but significant effect on systemic inflammatory and cardiovascular biomarkers.
Financial Disclosure
No funding was received for this research. Authors have no financial or proprietary interest in any product mentioned in the article. No author has any possible conflict of interest. The authors alone are responsible for the content and preparation of the paper.
Comments
-
